** Shares of drug developer Soleno Therapeutics SLNO.O fall ~6% to $54 premarket
** Co says U.S. FDA has extended review of its experimental drug to treat Prader–Willi syndrome, a rare genetic disorder
** The condition causes affected individuals to develop extreme hunger, which leads to chronic overeating, or hyperphagia, and obesity
** FDA determined that co's responses to recent information requests constituted major amendment to marketing application for the drug, diazoxide choline extended-release tablets
** The health regulator will now give its decision by March 27, 2025, compared with its previous action date of Dec. 27 this year
** FDA did not cite any safety, efficacy or manufacturing concerns, SLNO says
** Up to last close, stock up ~42% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。